Beta Bionics, Inc. (BBNX)

Company

Beta Bionics, Inc. (BBNX)

StatusJan 30, 2025
HealthHealth
Initial Public Offering / IPOInitial Public Offering / IPO

Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

IPO details
Prospectus volume (424B4)204 m USD12,000,000 shares · 17 USD/share

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Former names

NameUntil
Beta Bionics, IncJan 6, 2025

Chart/Sentiment

Financials

Beta Bionics, Inc. (BBNX)

Latest quarterly filing: 10-Q
Period endRevenue
2025-12-3110-K
100.3 m USD
2024-12-3110-K
65.1 m USD
2023-12-3110-K/A
12.0 m USD

Source: SEC Company Facts · USD. Some values may be calculated; please verify them against the official SEC filings.

Continue exploring

SPACSTAR Tools

Scroll to Top